CAP-CMV GmbH Raises New Funds to Further Develop its Novel hCMV Vaccine

News   Mar 25, 2014

 
CAP-CMV GmbH Raises New Funds to Further Develop its Novel hCMV Vaccine
 
 
 

RELATED ARTICLES

Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes Synthesis

News

TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.

READ MORE

Innate Immune Cells Reprogrammed to Fight Tuberculosis

News

A cure has eluded scientists for more than a century but, now, a Montreal team of researchers may have discovered a new weapon to combat this global killer. The team is re-programing - or 'training' - immune cells to kill TB. These groundbreaking findings are published online today in the journal Cell.

READ MORE

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE